Inclusion Criteria:

          -  Newly diagnosed locally advanced squamous cell carcinoma of cervix (Federation of
             Gynecology and Obstetrics [FIGO] 2018 stage IB3-IVA with primary tumor >= 5 cm and/or
             positive pelvic or periaortic nodal disease assessed by imaging)

          -  Histologic diagnosis of squamous cell carcinoma of the cervix

          -  Written informed consent before initiation of any study-related procedures

          -  World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) performance
             status 0-2

          -  Alanine aminotransferase (ALT) =< 2-fold the upper limit of normal

          -  Aspartate aminotransferase (AST) =< 2-fold the upper limit of normal

          -  Alkaline phosphatase (alk phos) =< 2-fold the upper limit of normal

          -  Total bilirubin (total bili) =< 2-fold the upper limit of normal

          -  Creatinine =< 1.5

          -  Electrocardiogram (ECG) with no clinically significant findings (as assessed by the
             investigator) performed within 30 days of signing the informed consent form

          -  Absence of current malignancies at other sites, except for adequately treated basal or
             squamous cell carcinoma of the skin. Cancer survivors who have undergone potentially
             curative therapy for a prior malignancy who have no evidence of that disease for 5
             years and who are deemed at low risk for recurrence are eligible for the study

        Exclusion Criteria:

          -  Human immunodeficiency virus (HIV) infection, cellular immune deficiencies,
             hypogammaglobulinemia or dysgammaglobulinemia, or hereditary or congenital
             immunodeficiencies

          -  Prior diagnosis of hepatitis B or C (unless anti-hepatitis C therapy has produced a
             sustained virologic response)

          -  History of clinically significant autoimmune disease, Crohn's disease, or ulcerative
             colitis

          -  Serious concomitant disorder, including active systemic infection requiring treatment,
             as judged by the investigator

          -  Receipt of immunotherapy (e.g., interferons [IFNs], check-point inhibitors, tumor
             necrosis factor, interleukins, etc.) or biological response modifiers
             (granulocyte-macrophage colony-stimulating factor [GM-CSF], granulocyte
             colony-stimulating factor, macrophage colony-stimulating factor) within 4 weeks before
             the first study vaccination

          -  Receipt of chronic systemic steroid therapy (in dosing exceeding 10 mg daily of
             prednisone equivalent) or any other form of immunosuppressive therapy within 7 days
             prior to the first dose of study drug

               -  Current or recent use of physiologic doses of intra-articular, topical, or
                  inhaled corticosteroids is acceptable

          -  History of previous therapeutic HPV vaccination (individuals who have been immunized
             with licensed prophylactic HPV vaccines [e.g., Silgard, Cervarix, Gardasil are not
             excluded)

          -  Known or suspected hypersensitivity to any component of the investigational product or
             contraindications to cisplatin (e.g., peripheral neuropathy grade =< 2 or ototoxicity
             =< grade 2 per Common Terminology Criteria for Adverse Events [CTCAE] version [v]5.0)

          -  Previous pelvic radiation therapy (RT)

          -  Previous chemotherapy for the cervix tumor

          -  Previous hysterectomy or will have a hysterectomy as part of their initial cervical
             cancer therapy

          -  Prior major surgery within 4 weeks of enrollment from which the patient has not
             recovered

          -  Other condition or prior therapy that, in the opinion of the Investigator, compromises
             the subject's welfare or may confound study results

          -  Concurrent participation in another therapeutic investigational study or use of
             another investigational drug within 6 months before the first study vaccination

          -  Previous enrollment in this study

          -  HPV genotyping is to be done from cervical swab samples. Enrollment will not require
             HPV testing

          -  Pregnancy: a female subject defined as a women of childbearing potential (WOCBP) who
             has a positive urine pregnancy test (e.g. within 72 hours) prior to treatment. If the
             urine test is positive or cannot be confirmed as negative, a serum pregnancy test will
             be required